Financhill
Sell
27

ELV Quote, Financials, Valuation and Earnings

Last price:
$373.07
Seasonality move :
3.48%
Day range:
$366.32 - $371.43
52-week range:
$362.21 - $567.26
Dividend yield:
1.76%
P/E ratio:
13.52x
P/S ratio:
0.50x
P/B ratio:
1.97x
Volume:
1.4M
Avg. volume:
2M
1-year change:
-20.51%
Market cap:
$86B
Revenue:
$171.3B
EPS (TTM):
$27.43

Analysts' Opinion

  • Consensus Rating
    Elevance Health has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $508.08, Elevance Health has an estimated upside of 36.99% from its current price of $370.89.
  • Price Target Downside
    According to analysts, the lowest downside price target is $388.00 representing 100% downside risk from its current price of $370.89.

Fair Value

  • According to the consensus of 18 analysts, Elevance Health has 36.99% upside to fair value with a price target of $508.08 per share.

ELV vs. S&P 500

  • Over the past 5 trading days, Elevance Health has underperformed the S&P 500 by -2.34% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Elevance Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Elevance Health has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Elevance Health reported revenues of $45.1B.

Earnings Growth

  • Elevance Health earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Elevance Health reported earnings per share of $4.36.
Enterprise value:
76.4B
EV / Invested capital:
1.08x
Price / LTM sales:
0.50x
EV / EBIT:
8.13x
EV / Revenue:
0.44x
PEG ratio (5yr expected):
1.76x
EV / Free cash flow:
87.77x
Price / Operating cash flow:
99.67x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
5.72%
Net Income Margin (TTM):
3.69%
Return On Equity:
15.67%
Return On Invested Capital:
9.55%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $153.2B $168.6B $174B $42.8B $45.1B
Gross Profit -- -- -- -- --
Operating Income -- -- -- -- --
EBITDA -- -- -- -- --
Diluted EPS $25.30 $25.47 $27.43 $5.45 $4.36
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $38.2B $44.6B $48.6B $55.7B $55.2B
Total Assets $86.6B $98.1B $103B $110.5B $116.5B
Current Liabilities $18.5B $21.5B $26.4B $27.3B $25.9B
Total Liabilities $52.7B $62.3B $67B $71.9B $72.7B
Total Equity $33.9B $35.8B $36B $38.5B $43.9B
Total Debt $20.8B $22.8B $23.8B $24.8B $27.1B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $11.6B $9.5B $2.1B $2.6B $2.7B
Cash From Investing -$5.8B -$4.3B -$4.6B -$687M -$401M
Cash From Financing -$2.4B -$3.2B -$609M -$994M -$915M
Free Cash Flow $10.4B $8.2B $871M $2.3B $2.3B
ELV
Sector
Market Cap
$86B
$45.6M
Price % of 52-Week High
65.38%
45.55%
Dividend Yield
1.76%
0%
Shareholder Yield
2.56%
-0.74%
1-Year Price Total Return
-20.51%
-31.35%
Beta (5-Year)
0.828
0.772
Dividend yield:
1.76%
Annualized payout:
$5.92
Payout ratio:
23.08%
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $371.12
200-day SMA
Sell
Level $497.99
Bollinger Bands (100)
Sell
Level 404.3 - 536.22
Chaikin Money Flow
Buy
Level 139.7M
20-day SMA
Sell
Level $387.65
Relative Strength Index (RSI14)
Sell
Level 33.97
ADX Line
Sell
Level 11.08
Williams %R
Buy
Level -81.8372
50-day SMA
Sell
Level $409.01
MACD (12, 26)
Sell
Level -13.56
25-day Aroon Oscillator
Sell
Level -48
On Balance Volume
Sell
Level -8.7M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (3.4997)
Buy
CA Score (Annual)
Level (-0.1133)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.1204)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.

Stock Forecast FAQ

In the current month, ELV has received 14 Buy ratings 4 Hold ratings, and 0 Sell ratings. The ELV average analyst price target in the past 3 months is $508.08.

  • Where Will Elevance Health Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Elevance Health share price will rise to $508.08 per share over the next 12 months.

  • What Do Analysts Say About Elevance Health?

    Analysts are divided on their view about Elevance Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Elevance Health is a Sell and believe this share price will drop from its current level to $388.00.

  • What Is Elevance Health's Price Target?

    The price target for Elevance Health over the next 1-year time period is forecast to be $508.08 according to 18 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.

  • Is ELV A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Elevance Health is a Buy. 14 of 18 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of ELV?

    You can purchase shares of Elevance Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Elevance Health shares.

  • What Is The Elevance Health Share Price Today?

    Elevance Health was last trading at $373.07 per share. This represents the most recent stock quote for Elevance Health. Yesterday, Elevance Health closed at $370.89 per share.

  • How To Buy Elevance Health Stock Online?

    In order to purchase Elevance Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
52
TSLL alert for Dec 24

Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.

Buy
73
PSIX alert for Dec 24

Power Solutions International [PSIX] is up 27.42% over the past day.

Sell
31
SOXL alert for Dec 24

Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock